Key facts
- This page summarizes Jonathan E. Lim's Form 3 filing for Maze Therapeutics, Inc. (MAZE).
- 0 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 30 Jan 2025, 16:34.
Jonathan E. Lim - 30 Jan 2025 Form 3 Insider Report for Maze Therapeutics, Inc. (MAZE)
- Reporting relationship
- Director
- Issuer ticker
- MAZE
- Reported as of
- 30 Jan 2025
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 30 Jan 2025, 16:34:12 UTC
- Prior SEC filing
- 21 Jun 2024
- Next SEC filing
- 05 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Courtney Phillips, as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jonathan E. Lim filed Form 3 for Maze Therapeutics, Inc. (MAZE) on 30 Jan 2025.
Change
- Previous filing in this sequence was filed on 21 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MAZE
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 20,744
- Date
- 30 Jan 2025
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MAZE
holding
Derivative
Series A Preferred Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 30 Jan 2025
- Ownership
- City Hill, LLC
- Underlying class
- Common Stock
- Underlying amount
- 363,703
- Exercise price
- Footnotes
- F1, F2
MAZE
holding
Derivative
Series B Preferred Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 30 Jan 2025
- Ownership
- City Hill, LLC
- Underlying class
- Common Stock
- Underlying amount
- 2,231,381
- Exercise price
- Footnotes
- F2, F3
MAZE
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 30 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,704
- Exercise price
- $10.42
- Footnotes
- F4
MAZE
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 30 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 9,086
- Exercise price
- $10.42
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Pursuant to the Issuer's Restated Certificate of Incorporation, each share of Series A Convertible Preferred Stock may be converted, at the option of the holder, at any time. In connection with the completion of the Issuer's initial public offering of its Common Stock, each share of Series A Convertible Preferred Stock shall automatically convert into shares of Common Stock at a ratio of 1-for- 0.1037236801. The securities have no expiration date.
Footnote F2
These securities are directly held by City Hill, LLC, of which the reporting person is the managing partner.
Footnote F3
Pursuant to the Issuer's Restated Certificate of Incorporation, each share of Series B Convertible Preferred Stock may be converted, at the option of the holder, at any time. In connection with the completion of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock shall automatically convert into shares of Common Stock at a ratio of 1-for-0.1211056427. The securities have no expiration date.
Footnote F4
The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on April 1, 2023, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Footnote F5
The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.